Animal Models Of Cognitive Impairment

The costs associated with a drug’s clinical trials are so significant that it has become necessary to validate both its safety and efficacy in animal models prior to the continued study of the drug in humans. Featuring contributions from distinguished researchers in the field of cognitive therapy research, Animal Models of Cognitive Impairment examines some of the most popular and successful animal archetypes used in the context of drug discovery. It provides integrated coverage of the latest research concerning neuronal systems relevant to cognitive function and dysfunction, assimilating reviews of this research within the context of each chapter. This approach is unique in that it brings together molecular and neurochemical methodologies, behavioral applications in translational models, and clinical applications. The book comprehensively discusses a wide variety of animal models of cognitive impairment, including genetic, lesion, pharmacological, and aging related impairments. It also explores the significance of this research in regards to the treatment of various addictions and disorders such as stroke, autism, Alzheimer’s, schizophrenia, and ADHD. Edited by two renowned authorities in the field, Animal Models of Cognitive Impairment is a timely book that provides integrated coverage of cutting-edge research that concerns neuronal systems relevant to cognitive function and dysfunction.

With an ever-increasing elderly population and the resultant rising levels of dementia-related disorders, preclinical research based on animal models is pivotal to our knowledge of underlying molecular mechanisms and drug discovery aiming at the development of therapeutic strategies alleviating or preventing the neurological devastation. In Animal Models of Dementia, expert researchers provide contributions that stress the importance of extensively validated animal models in drug discovery and development in order to predict clinical activity. Beginning with general aspects of animal modeling, related ethical issues, and essential methodological considerations, the highly detailed volume then continues with various levels of model validation, including pathological, behavioral, neurochemical, pharmacological, and imaging aspects, followed by sections focused on specific disorders, such as Alzheimer’s disease, Parkinson’s disease, metachromatic leukodystrophy and adrenoleukodystrophy, amyotrophic lateral sclerosis, frontotemporal dementia as well as vascular dementia and more. As a volume in the renowned Neuromethods series, this book offers a detailed, yet accessible, overview of currently available animal models in the field of dementia research, and touches, as well, upon more general areas linked to the development and use of animal models. Comprehensive and efficient, Animal Models of Dementia will significantly aid both experienced animal researchers as well as investigators on the verge of beginning animal model-based dementia research.

Using the most well-studied behavioral analyses of animal subjects to promote a better understanding of the effects of disease and the effects of new therapeutic treatments on human cognition, Methods of Behavior Analysis in Neuroscience provides a reference manual for molecular and cellular research scientists in both academia and the pharmaceutic

Neurodegenerative diseases are the most frequent cause of dementia, representing a burden for public health systems (especially in middle and middle-high income countries). Although most research on this issue is concentrated in first-world centers, growing efforts in South America are affording important breakthroughs. This emerging agenda poses new challenges for the region but also new opportunities for the field. This book aims to integrate the community of experts across the globe and the region, and to establish new challenges and developments for future investigation. We present research focused on neurodegenerative research in South America. We introduce studies assessing the interplay among genetic, neural, and behavioral dimensions of these diseases, as well as articles on vulnerability factors, comparisons of findings from various countries, and works promoting multicenter and collaborative networking. More generally, our book covers a broad scope of human-research approaches (behavioral assessment, neuroimaging, electromagnetic techniques, brain connectivity, peripheral measures), animal methodologies (genetics, epigenetics, proteomics, metabolomics, other molecular biology tools), species (all human and non-human animals, sporadic, and genetic versions), and article types (original research, review, and opinion papers). Through this wide-ranging proposal, we hope to introduce a fresh approach to the challenges and opportunities of research on neurodegeneration in South America.

Senile dementia is one of the major health problems confronting mankind in this century. To some extent the problem has, of course, always existed. The condition was sufficiently troubling to classical philosophers and jurists to have apparently provoked comments by Solon in approximately 500 B. C. and Plato in the fourth century B. C. (Plutarch 1967 translation; Plato 1921 translation). Medical recognition can be traced at least as far back as the second century A. D. (Adams 1861). However, several factors have converged in this century to extend the absolute dimensions of the problem of senile dementia and to increase societal, medical, and scientific recogni tion of the magnitude of the condition. Perhaps the most important factor relating to the present importance of senile dementia is demographic. Although the human population has been increasing since the mid-eighteenth century, it has only been since the advent of the twentieth century that a decrease in mortality has been noted for those over the age of 45 (McKeown 1976). Consequently, the absolute number of aged persons and the proportion of increasingly aged persons in the populations of the world's industrial nations have been steadily increasing. For example, in the United States, 4% ofthe population was over the age of 65 in 1900. In the 1970 census, this proportion had grown to 10%.

Significant improvements in lifestyle and medical science are leading to an ever increasing elderly population in the United States and other developed nations. The U.S census bureau estimates that the number of people over 65 will nearly double by 2030, and that the elderly will comprise nearly one-fifth of the world’s entire population within the next 20 years. In Animal Models of Human Cognitive Aging, Jennifer Bizon, Alisa Woods, and a panel of international authorities comprehensively discuss the use of animal models as a tool for understanding cognitive changes associated with the aging process. The book provides substantive background on the newest and most widely used animal models in studies of cognition and aging, while detailing the normal and pathological processes of brain aging of humans in relation to those models. Additional chapters comprehensively review frontal cortical deficits and executive function in primates as related to humans, and the use of transgenic modulation in mice to model Alzheimer’s and other age-related diseases. Groundbreaking and authoritative, Animal Models of Human Cognitive Aging provides a valuable resource for Neuroscientists, Gerontological Scientists and all aging medicine researchers, while serving as a primer for understanding current brain aging studies.

Negative Affective States and Cognitive Impairments in Nicotine Dependence is the only book of its kind that addresses nicotine use and abuse in the context of negative reinforcement mechanisms. Written and edited by leading investigators in addiction, affective, genetic, and cognitive research, it provides researchers and advanced students with an overview of the clinical bases of these effects, allowing them to fully understand the various underlying dysfunctions that drive nicotine use in different individuals. In addition, this book examines animal models that researchers have utilized to investigate the biological bases of these dysfunctions. The combination of clinical and preclinical approaches to understanding nicotine dependence makes this book an invaluable resource for researchers and practitioners seeking to develop targeted treatments aimed at ameliorating symptoms of nicotine dependence, as well as identifying premorbid differences in affective or cognitive function. Provides a unique perspective on nicotine dependence that emphasizes negative reinforcement rather than positive reinforcement Examines psychiatric comorbidities and alleviation of withdrawal states as motivation for continued tobacco use Includes both clinical and preclinical perspectives Includes genetic and multi-neurotransmitter perspectives on nicotine use and withdrawal Emphasizes heterogeneity of underlying reasons for smoking, the need for multiple animal models to understand this heterogeneity, and the expectation of heterogeneous responses to potential treatments, underscoring the need for personalized therapeutics

Recognition that aging is not the accumulation of disease, but rather comprises fundamental biological processes that are amenable to experimental study, is the basis for the recent growth of experimental biogerontology. As increasingly sophisticated studies provide greater understanding of what occurs in the aging brain and how these changes occur